Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 138

1.

Validation and clinicopathologic associations of a urine-based bladder cancer biomarker signature.

Zhang G, Gomes-Giacoia E, Dai Y, Lawton A, Miyake M, Furuya H, Goodison S, Rosser CJ.

Diagn Pathol. 2014 Nov 12;9:200. doi: 10.1186/s13000-014-0200-1.

2.

External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort.

Chen LM, Chang M, Dai Y, Chai KX, Dyrskj√łt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, Parker AS, Ross S, Borre M, Orntoft TF, Jaeger T, Beukers W, Lopez LE, Henrique R, Young PR, Urquidi V, Goodison S, Rosser CJ.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1804-12. doi: 10.1158/1055-9965.EPI-14-0029. Epub 2014 Jun 11.

PMID:
24920641
3.

Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.

Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L, Egan JO, Rhode PR, Parker AS, Chai KX, Wong HC, Rosser CJ.

PLoS One. 2014 Jun 4;9(6):e96705. doi: 10.1371/journal.pone.0096705. eCollection 2014.

4.

Matrix metalloproteinase-10 promotes tumor progression through regulation of angiogenic and apoptotic pathways in cervical tumors.

Zhang G, Miyake M, Lawton A, Goodison S, Rosser CJ.

BMC Cancer. 2014 May 3;14:310. doi: 10.1186/1471-2407-14-310.

5.

Urinary protein biomarker panel for the detection of recurrent bladder cancer.

Rosser CJ, Chang M, Dai Y, Ross S, Mengual L, Alcaraz A, Goodison S.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1340-5. doi: 10.1158/1055-9965.EPI-14-0035. Epub 2014 Apr 8.

6.

Simultaneous multi-analyte urinary protein assay for bladder cancer detection.

Rosser CJ, Dai Y, Miyake M, Zhang G, Goodison S.

BMC Biotechnol. 2014 Apr 1;14:24. doi: 10.1186/1472-6750-14-24.

7.

Angiogenin promotes tumoral growth and angiogenesis by regulating matrix metallopeptidase-2 expression via the ERK1/2 pathway.

Miyake M, Goodison S, Lawton A, Gomes-Giacoia E, Rosser CJ.

Oncogene. 2015 Feb 12;34(7):890-901. doi: 10.1038/onc.2014.2. Epub 2014 Feb 24.

PMID:
24561529
8.

MULTIPLEX URINARY TESTS FOR BLADDER CANCER DIAGNOSIS.

Urquidi V, Rosser CJ, Goodison S.

Eur Med J Urol. 2013;1:70-73.

9.

Clinical implications in the shift of syndecan-1 expression from the cell membrane to the cytoplasm in bladder cancer.

Miyake M, Lawton A, Dai Y, Chang M, Mengual L, Alcaraz A, Goodison S, Rosser CJ.

BMC Cancer. 2014 Feb 13;14:86. doi: 10.1186/1471-2407-14-86.

10.

PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation.

Giacoia EG, Miyake M, Lawton A, Goodison S, Rosser CJ.

Mol Cancer Res. 2014 Mar;12(3):322-34. doi: 10.1158/1541-7786.MCR-13-0543. Epub 2014 Jan 24.

11.

The Postoperative Morbidity Index: a quantitative weighing of postoperative complications applied to urological procedures.

Beilan J, Strakosha R, Palacios DA, Rosser CJ.

BMC Urol. 2014 Jan 3;14:1. doi: 10.1186/1471-2490-14-1.

12.

Differential expression of SDF-1 isoforms in bladder cancer.

Gosalbez M, Hupe MC, Lokeshwar SD, Yates TJ, Shields J, Veerapen MK, Merseburger AS, Rosser CJ, Soloway MS, Lokeshwar VB.

J Urol. 2014 Jun;191(6):1899-905. doi: 10.1016/j.juro.2013.11.053. Epub 2013 Nov 26.

13.

Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer.

Miyake M, Lawton A, Goodison S, Urquidi V, Rosser CJ.

Pathol Res Pract. 2014 Feb;210(2):74-8. doi: 10.1016/j.prp.2013.08.013. Epub 2013 Oct 28.

PMID:
24252309
14.

Pilot study comparing the two hemostatic agents in patients undergoing partial nephrectomy.

Palacios DA, McDonald M, Miyake M, Rosser CJ.

BMC Res Notes. 2013 Oct 3;6:399. doi: 10.1186/1756-0500-6-399.

15.

Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.

Gomes-Giacoia E, Miyake M, Goodison S, Rosser CJ.

Mol Cancer Ther. 2013 Dec;12(12):2697-708. doi: 10.1158/1535-7163.MCT-13-0500. Epub 2013 Sep 26.

16.

Urinary biomarkers of bladder cancer: an update and future perspectives.

Rosser CJ, Urquidi V, Goodison S.

Biomark Med. 2013 Oct;7(5):779-90. doi: 10.2217/bmm.13.73. Review.

PMID:
24044570
17.

Investigation of CCL18 and A1AT as potential urinary biomarkers for bladder cancer detection.

Miyake M, Ross S, Lawton A, Chang M, Dai Y, Mengual L, Alcaraz A, Giacoia EG, Goodison S, Rosser CJ.

BMC Urol. 2013 Sep 5;13:42. doi: 10.1186/1471-2490-13-42.

18.

Erythropoietin is a JAK2 and ERK1/2 effector that can promote renal tumor cell proliferation under hypoxic conditions.

Miyake M, Goodison S, Lawton A, Zhang G, Gomes-Giacoia E, Rosser CJ.

J Hematol Oncol. 2013 Sep 3;6:65. doi: 10.1186/1756-8722-6-65.

19.

Attitudes and knowledge of primary care physicians regarding prostate cancer screening.

Johnson K, Chang M, Sun Y, Miyake M, Rosser CJ.

J Cancer Educ. 2013 Dec;28(4):679-83. doi: 10.1007/s13187-013-0533-6.

PMID:
23963724
20.

Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers.

Miyake M, Lawton A, Goodison S, Urquidi V, Gomes-Giacoia E, Zhang G, Ross S, Kim J, Rosser CJ.

BMC Cancer. 2013 Jul 1;13:322. doi: 10.1186/1471-2407-13-322.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk